Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP517195.RANleRfojozq6grCsnx24QhbaaLhxxUhz-wmbzwQYqPWI130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP517195.RANleRfojozq6grCsnx24QhbaaLhxxUhz-wmbzwQYqPWI130_assertion type Assertion NP517195.RANleRfojozq6grCsnx24QhbaaLhxxUhz-wmbzwQYqPWI130_head.
- NP517195.RANleRfojozq6grCsnx24QhbaaLhxxUhz-wmbzwQYqPWI130_assertion description "[However, gemcitabine, paclitaxel, or cisplatin treatment enhanced the Akt activation, heterodimer formation of EGFR with HER3, and secretion of amphiregulin, indicating that the presence of gemcitabine promoted the activity of targeted molecules including amphiregulin, Akt, and HER3 for pancreatic cancer therapy.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP517195.RANleRfojozq6grCsnx24QhbaaLhxxUhz-wmbzwQYqPWI130_provenance.
- NP517195.RANleRfojozq6grCsnx24QhbaaLhxxUhz-wmbzwQYqPWI130_assertion evidence source_evidence_literature NP517195.RANleRfojozq6grCsnx24QhbaaLhxxUhz-wmbzwQYqPWI130_provenance.
- NP517195.RANleRfojozq6grCsnx24QhbaaLhxxUhz-wmbzwQYqPWI130_assertion SIO_000772 20726858 NP517195.RANleRfojozq6grCsnx24QhbaaLhxxUhz-wmbzwQYqPWI130_provenance.
- NP517195.RANleRfojozq6grCsnx24QhbaaLhxxUhz-wmbzwQYqPWI130_assertion wasDerivedFrom befree-20140225 NP517195.RANleRfojozq6grCsnx24QhbaaLhxxUhz-wmbzwQYqPWI130_provenance.
- NP517195.RANleRfojozq6grCsnx24QhbaaLhxxUhz-wmbzwQYqPWI130_assertion wasGeneratedBy ECO_0000203 NP517195.RANleRfojozq6grCsnx24QhbaaLhxxUhz-wmbzwQYqPWI130_provenance.